Himmelfarb J, Vanholder R, Mehrotra R, Tonelli M. The current and future landscape of dialysis. Nat Rev Nephrol. 2020;16(10):573–85.

PubMed  PubMed Central  Article  Google Scholar 

Acosta-Ochoa I, Bustamante-Manguira J, Mendiluce-Herrero A, Bustamante-Bustamante J, Coca-Rojo A. Impact on outcomes across KDIGO-2012 AKI criteria according to baseline renal function. J Clin Med. 2019;8(9).

Park S, Choi YJ, Kang JE, et al. P2Y12 Antiplatelet choice for patients with chronic kidney disease and acute coronary syndrome: a systematic review and meta-analysis. J Personalized Med. 2021;11(3):222.

Article  Google Scholar 

Jain N, Reilly RF. Oral P2Y12 Receptor inhibitors in hemodialysis patients undergoing percutaneous coronary interventions: current knowledge and future directions. Semin Dial. 2016;29(5):374–81.

PubMed  Article  Google Scholar 

Best PJM, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39(7):1113–9.

PubMed  Article  Google Scholar 

Alkhalil M, McCune C, McClenaghan L, et al. Comparative analysis of the effect of renal function on the spectrum of coronary artery disease. Am J Med. 2020;133(11).

Lai A, Bienstock SW, Sharma R, et al. A Personalized approach to chronic kidney disease and cardiovascular disease. J Am Coll Cardiol. 2021;77(11):1470–9.

PubMed  Article  Google Scholar 

Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.

CAS  PubMed  Article  Google Scholar 

Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.

CAS  PubMed  Article  Google Scholar 

Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

CAS  PubMed  Article  Google Scholar 

Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2014;34(10):1077–90.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Valgimigli M, Bueno H, Byrne R, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with eacts. Eur Heart J. 2017;39(3):213–60.

Article  Google Scholar 

Bonello L, Angiolillo DJ, Aradi D, Sibbing D. P2Y12-ADP receptor blockade in chronic kidney disease patients with acute coronary syndromes review of the current evidence. Circulation. 2018;138(15):1582–96.

CAS  PubMed  Article  Google Scholar 

Huang M, Wei R, Wang Y, et al. Blood coagulation system in patients with chronic kidney disease: a prospective observational study. BMJ Open. 2017;7(5).

Takagi M, Wada H, Mukai K, et al. Increased activated protein C: protein C inhibitor complex and decreased protein C inhibitor levels in patients with chronic renal failure on maintenance hemodialysis. Clin Appl Thromb Hemost. 1999;5:113–6.

CAS  PubMed  Article  Google Scholar 

Lisman T. Decreased plasma fibrinolytic potential as a risk for venous and arterial thrombosis. Semin Thromb Hemost. 2016;43(02):178–84.

PubMed  Article  CAS  Google Scholar 

NikolovaVlahova M, Baleva MP, Nikolov PK. Thromboembolism in renal diseases. Embolic Diseases - Unusual Therapies and Challenges. 2017.

Holden RM, Harman GJ, Wang M, Holland D, Day AG. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(1):105–10.

PubMed  PubMed Central  Article  Google Scholar 

Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metabol Toxicol. 2008;4(8).

Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant. 2018;33:iii35–iii40. https://doi.org/10.1093/ndt/gfy175

Foley R, Herzog C, Collins A. Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 study. Kidney Int. 2003;63(4):1462–7. https://doi.org/10.1046/j.1523-1755.2003.00860.x

Joki N, Hase H, Nakamura R, Yamaguchi Y. Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant. 1997;12(4):718–23.

CAS  PubMed  Article  Google Scholar 

Surana S, Riella LV, Keith-Reddy AR, Charytan DM, Singh AK. Acute coronary syndrome in ESRD patients. Kidney Int. 2009;75(5):558–62. https://doi.org/10.1038/ki.2008.233

Madhavan M.V., Tarigopula M, Mintz G.S., Maehara A, Stone G.W., Genereux P. Coronary artery calcification: pathogenesis and prognostic implications. J Am Coll Cardiol. 2014;63(17):1703–14. https://doi.org/10.1016/j.jacc.2014.01.017

Van Biesen W, Verbeke F, Vanholder R. Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis. Nephrol Dial Transplant. 2006;22(1):53–8. https://doi.org/10.1093/ndt/gfl601

Nicol M, Siguret V, Vergaro G, et al. Thromboembolism and bleeding in systemic amyloidosis: a review. ESC Heart Failure. 2022;9(1):11–20.

PubMed  Article  Google Scholar 

Cappelli F, Tini G, Russo D, et al. Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2020;28:1–7.

Google Scholar 

Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007;116:2420–6.

PubMed  Article  Google Scholar 

Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107(1):87–92.

CAS  PubMed  Article  Google Scholar 

Held C, White HD, Stewart RAH, et al. Inflammatory biomarkers interleukin‐6 and C‐reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial. J Am Heart Assoc. 2017.

Ridker, P. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circulation. 2016.

Yu M, Xie R, Zhang Y, et al. Phosphatidylserine on microparticles and associated cells contributes to the hypercoagulable state in diabetic kidney disease. Nephrol Dial Transplant. 2018.

Lutz J, Menke J, Sollinger D, Schinzel H, Thurmel K. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2013;29(1):29–40.

PubMed  Article  CAS  Google Scholar 

Stähli B, Gebhard C, Duchatelle V, et al. Effects of the P‐selectin antagonist Inclacumab on myocardial damage after percutaneous coronary intervention according to timing of infusion: insights from the SELECT‐ACS Trial. J Am Heart Assoc. 2016;5(11):e004255. https://doi.org/10.1161/JAHA.116.004255

Mörtberg J, Lundwall K, Mobarrez F, Wallen H, Jacobson SH, Spaak J. Increased concentrations of platelet- and endothelial-derived microparticles in patients with myocardial infarction and reduced renal function- a descriptive study. BMC Nephrol. 2019;20(1):71. https://doi.org/10.1186/s12882-019-1261-x

Gäckler A, Rohn H, Lisman T, et al. Evaluation of hemostasis in patients with end-stage renal disease. PLoS One. 2019;14(2):e0212237. https://doi.org/10.1371/journal.pone.0212237

Brunet P, Aillaud MF, San Marco M, et al. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int. 1995;48(3):794–800. https://doi.org/10.1038/ki.1995.352

Best PJM, Steinhubl SR, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155(4):687–93.

CAS  PubMed  Article  Google Scholar 

Mangiacapra F, Cavallari I, Barbato E, et al. Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention. Am J Cardiol. 2014;113(7):1124.

PubMed  Article  Google Scholar 

Gremmel T, Muller M, Steiner S, et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant. 2013;28(8):2116–22.

CAS  PubMed  Article  Google Scholar 

Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol. 2009;104(9):1292–5.

CAS  PubMed  Article  Google Scholar 

Jain N, Li X, Adams-Heut B, et al. Differences in whole blood platelet aggregation at baseline and in response to aspirin and aspirin plus clopidogrel in patients with versus without chronic kidney disease. Am J Cardiol. 2016;117(4):656–63.

CAS  PubMed  Article  Google Scholar 

Breet NJ, Van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303(8):754.

CAS  PubMed  Article  Google Scholar 

Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. JAMA. 2011;305(11):1097.

CAS  PubMed  Article  Google Scholar 

Jeong KH, Cho JH, Woo JS, et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. Am J Kidney Dis. 2015;65(6):916–24.

CAS  PubMed  Article  Google Scholar 

Alexopoulos D, Pangiotou A, Xanthopoulou I, et al. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J Thromb Haemost. 2011;9(12):2379–85.

CAS  PubMed  Article  Google Scholar 

Kamada T, Iwasaki M, Konishi A, et al. A pharmacodynamics comparison of prasugrel and clopidogrel in patients undergoing hemodialysis. Heart Vessels. 2019;34(6):883–7.

PubMed  Article  Google Scholar 

Ohno Y, Kitahara H, Fujii K, et al. High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis. J Cardiol. 2019;73(1):51–7.

PubMed  Article  Google Scholar 

Alexopoulos D, Xanthopoulou I, Plakomyti T, Goudas P, Koutroulia E, Goumenos D. Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. Am J Kidney Dis. 2012;60(2):332–3.

PubMed  Article  Google Scholar 

Kim JS, Woo JS, Kim JB, et al. The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. Int J Cardiol. 2017;238(1):110–6.

PubMed  Article  Google Scholar 

Lee CH, Tsai T, Lin C, Hsueh S, Chung W, Cheng C. Efficacy and safety of ticagrelor compared with clopidogrel in patients with end-stage renal disease with acute myocardial infarction. Am J Cardiovasc Drugs. 2019;19(3):325–34.

CAS  PubMed  Article  Google Scholar 

Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;42(14):1289–367.

Article  Google Scholar 

Natale P, Palmer SC, Saglimbene VM, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2022.

Burlacu A, Genovesi S, Ortiz A, et al. Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrol Dial Transplant. 2019;34(6):923–33.

PubMed  Article  Google Scholar 

Al